Galderma, a part of Nestlé Skin Health, has announced a positive outcome of the European Decentralised Procedure for Soolantra (ivermectin) cream 10mg/g, a new treatment for rosacea in adult patients.
This will allow the product, available in the United States since February, to be launched in 28 European Union countries.
Rosacea is a common inflammatory skin disease characterised by several symptoms including flushing, pimples and inflammatory lesions. It mainly affects the central areas of the face, such as the cheeks and nose, in both adult men and women after the age of 30.
Read the press release on the Galderma website.